Australia
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
SYDNEY, Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities (PIP...
2025-08-01 20:00
5663
A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US
All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months SYDNEY, July 22, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) is encouraging individu...
2025-07-22 20:00
2776
Co-PSMA trial: Recruitment successfully completed
SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...
2025-07-17 21:01
4452
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of d...
2025-07-09 20:00
4213
Mindsprint enhances ProcureSPRINT™ with Agentic AI to unlock up to 15% in procurement cost efficiencies
SINGAPORE, July 9, 2025 /PRNewswire/ -- Mindsprint
2025-07-09 14:37
2872
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: * Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement * Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing da...
2025-07-03 07:09
4630
Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
Interim analysis planned for January 2026 with final trial results in late 2026 Highlights: * With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed forJanuary 2026 and the timeline for final results reconfirmed for late 2026 * An...
2025-06-30 20:30
2909
QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA
BRISBANE, Australia, June 25, 2025 /PRNewswire/ -- QBiotics CEO, Stephen Doyle, reflecting on Soft Tissue Sarcoma data * Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced S...
2025-06-25 18:05
2700
Academic friend or foe? Yugo research reveals how students supercharge their studies with AI
Despite academic advantages, substantial fears remain about AI's impact
LONDON, June 19, 2025 /PRNewswire/ -- As universities grapple with how to
effectively police AI, new Yugo research reveals the extent to which students
are using it as a powerful study companion.
2025-06-19 05:33
2820
Largest Australian Health Insurer to Fund Innovative PTSD Treatment Program
PERTH, Australia, June 18, 2025 /PRNewswire/ -- Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, today announced a landmark partnership with Medibank, Australia's largest private health insurer. Under the multi-yea...
2025-06-18 20:00
3377
Polus holds €425 million initial close for third CLO equity fund
One of Europe's largest raises of its kind highlights Polus' leadership in the CLO and leveraged credit markets. LONDON, June 17, 2025 /PRNewswire/ -- Polus Capital Management ("Polus"), an investment management firm specialising in alternative credit strategies, is pleased to announce the initi...
2025-06-17 22:18
2581
Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
Highlights * Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for64Cu-SAR-bisPSMA. * SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both copper-64 and64Cu-SAR-bisPSMA under one roof and enables distribution to all 50 sta...
2025-06-17 21:04
4690
Ace Green Recycling and Enecell Announce Strategic Agreement to Advance Sustainable Battery Recycling in Australia
Ace to become Enecell's exclusive offtake partner for its lead battery
recycling facility inPerth
Commercial agreement is Ace's first in Australia, the world's largest lithium
producer
HOUSTON, June 16, 2025 /PRNewswire/ -- Ace Green Recycling
2025-06-16 20:00
3045
PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL
HIGHLIGHTS * A confirmed pathological complete response has been recorded in the ACCENT trial * A pathological complete response (pCR) is extremely rare in patients undergoing treatment for advanced pancreatic cancer * A pCR means that there are no signs of cancer in tissue examined by a p...
2025-06-16 19:00
2270
NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Highlights: * NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease * Treatment prevented hallmark developmental and morphological abnormalities, protected against neuronal cell death, restored delayed h...
2025-06-16 19:00
3954
SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging
Highlights * Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64 Cu-SAR-Bombesin was safe, well tolerated and effective at detecting prostate cancer in patients with biochemical recurrence (BCR) who are negative or equivocal on standard-of-care (SOC) scans, including pr...
2025-06-13 21:01
4298
U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma
MELBOURNE, Australia, June 13, 2025 /PRNewswire/ -- On 7 May 2025, the FDA approved an IND application enabling Myrio's lead product (PHOX2B PC-CAR T) to enter human trials. Myrio, in collaboration the leading children's hospital in Philadelphia have co-developed a Chimeric Antigen Receptor (CAR-T...
2025-06-13 19:35
3783
Dazu Rock Carvings: The Last Monument of World Grotto Art
CHONGQING, China, June 12, 2025 /PRNewswire/ -- Located in southwest China's Chongqing Municipality, the Dazu Rock Carvings have held UNESCO World Heritage status since 1999. Sprawled across 75 recognized cultural relics protection zones, the site shelters over 50,000 breathtaking statues. As one...
2025-06-12 23:29
3325
Cam Model Earned Over $3.4 Million Streaming on LiveJasmin -- 3rd Edition of International Cam Model Day Celebrates a New Era of Creator Careers
LiveJasmin marks model appreciation week and 25 years in the industry with new
opportunities to empower models onwww.cammodelday.com
2025-06-12 01:09
2929
Uzbekistan Sees Foreign Investment Growth of over 60 per cent in 2024
'New Uzbekistan: The Big Country With Big Opportunities – Reform In Action' FDI Report unveiled as Tashkent International Investment Forum Gets Underway TASHKENT, Uzbekistan, June 10, 2025 /PRNewswire/ -- Foreign investment in Uzbekistan is growing rapidly as the country saw an over 60 per cent ...
2025-06-10 17:00
3242
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 295 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 272 media titles]
2026-09-21 08:00Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
11143
COSRX Brings Its 5 Peptide Lip Collection to Ulta Beauty Stores Offline
2026-09-18 22:00
9463
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
8782
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
2026-09-15 19:07
7039
